About

Founded

2019

Headquarters

South San Francisco, California

Industry

Healthcare, Biotech

Company Description

Arsenal Biosciences, Inc. is a clinical stage, programmable cell therapy company focused on solid tumor cell therapies to defeat cancer.

Quick Links

Website Jobs

Funding

Total Raised

$305.8 million

Valuation

Undisclosed

Significant Investors

Kleiner Perkins, Westlake Village, Euclidean Capital, SoftBank, Bristol-Myers Squibb Company, Byers Capital, Emerson Collective Investments, Green Sands, Hitachi Ventures, Sixth Street, PICI, Waycross Ventures, UCSF

Company Traction

In May 2023, ArsenalBio shared pre-clinical data on AB-1015 (ovarian cancer) and AB-2100 (kidney cancer).

In January 2023, ArsenalBio reported its first patient was dosed in a phase 1 clinical trial of AB-1015 in the development of treatment for ovarian cancer.

Leadership Team

Ken Drazan: Co-Founder, CEO, and Chairman of ArsenalBio. Former President at Grail.

Susie Jun: Chief Medical Officer at ArsenalBio. Former Chief Development Officer at Allogene Therapeutics.

Tarjei Mikkelsen: CTO at ArsenalBio. Former VP of Biology at 10x Genomics.

Bee Nguyen: Chief People Officer at ArsenalBio. Former VP of Human Resources at Ultragenyx.

Tim Sirichoke: Chief Technical Operations Officer at ArsenalBio. Former VP, Head of iNeST Manufacturing at Genentech.

Press

Fierce Biotech (September 6, 2022): BMS-backed Arsenal Bio pulls trigger on $220M series B, touting potential fleet of gene-edited cell therapies

TechCrunch (October 17, 2019): ArsenalBio emerges from stealth with $85 million and a dream team to fight cancer

ArsenalBio